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INTRODUCTION
Since the seventeenth century, difficulty has arisen from blood trans-
fusions, due to some unknown factors.
For some years prior to 1900, many research workers in the field of
bacteriology had been engaged in an extension of the knowledge that the
animal body would react with, or show an immune response to, a wide variety
of foreign materials and agents, called "antigens". This response could be
studied experimentally by the occurance or development of mysterious prop-
erties, or substances in the blood stream and fluids of the body which would
react with the antigens—to which the term "antibodies" was given. These
antibodies manifested themselves differently in their reactions against
material foreign to them—to antigenic substances.
In 1900, searching for individual differences in human blood, Land-
steiner (Race and Sanger, 13) selected the simplest technique possible,
namely, to mix the serum of one individual with the red cells of others.
By this method, he found that the blood fell into three blood groups. The
fourth and rarest group, AB, was not discovered until the following year by
DeCastello and Sturli (Andresen, 1).
Discovery of the agglutinogens M, N, and P came next but have proved of
little importance for the selection of donors for blood transfusions, because
isoantibodies for M, N, and P occur only rarely in human sera.
Intragroup reactions seemed to indicate that there were more factors
involved. In 19U0, Landsteiner and Wiener (Race and Sanger, 13j Race, Ik)
discovered the Rh factor and they, along with others, explained that these
unexpected reactions might be due to the Rh factors. After much work, very
2potent anti-Rh sera of human origin have been produced and made available
to the public.
Prior to discovery of the Rh factor, all blood typing was directed
toward the use of anti-A and anti-B serums for the selection of donors for
patients belonging to a particular blood group. Soon after doctors became
aware of the fact that the Rh factor was important as a canse of severe
transfusion reactions in their patients, it was also shown that the Rh factor
was involved in hemolytic disease of newborn infants thus discovery of
the Rh or rhesus blood factor has supplied the key to two medical mysteries,
namely, the cause of hemolytic transfusion reactions in patients receiving
blood of their own A-B-0 group, and the cause of an obscure blood disease of
newborn infants known as erythroblastosis fetalis.....hence the wide use of
Rh typing serums in present day obstetrical and blood banking practices.
The blood group substances are not yet as individual as finger prints,
but their inheritance is known much more precisely. The groups are deter-
mined by antigens present on the red blood cells; and an antigen is recog-
nized when the cells carrying it are clumped, or agglutinated, by a serum
containing the corresponding antibody.
At the present ti^e a minimum of six Rh factors are recognized, giving
rise, theoretically, to six anti-sera, by means of which it is possible to
recognize eight distinct Rh blood types. Some of these anti sera are readily
obtained, other much needed ones are difficult to prepare.
After observing the lengthy process of producing the anti-rh' sera of
human origin (sometimes requiring injections over a period of a year or more
to secure a titer sufficient for testing) and reading many articles and re-
views of previous work, the author wondered if—by injecting the New Zealand
white rabbit with the cells of an individual whose type was that of rh'—
a
3suitable anti-serum might be produced in a shorter time.
The source of material for this study was secured from the Topeka Blood
Bank, Sharp and Dohme, Inc., American Hospital Supply Corporation (Dade
Reagents, Inc.), and Mr, John Shaffer of Topeka, Kansas.
PRESENT STATUS OF THE RH FACTOR
The Rh or rhesus factor obtained its name when the first antisera were
prepared by Landsteiner and Wiener ( T.'iener, 18) in 1°U0, by injecting into
experimental animals blood of rhesus monkeys. At present, antiserums of
human origin are usually used, either from patients who have had intragroup
hemolytic reactions, or from mothers of erythroblastotic infants, or from
normal male individuals immunized by repeated injections of Rh positive
blood.
Of the human Rh antisera, the one corresponding to the original anti-
rhesus serum, reacting with the bloods of approximately 85 percent of Cau-
casians, has been designated as anti-Rho. For the other two antisera has
been selected the small letter designations anti-rh' for the one giving 70
percent positive reactions, and anti-rh 1 • for the one giving 30 percent
positive reactions, to indicate that these two antisera are on an equal plane
and to distinguish them from the more important anti-Rho serum.
Levine and Javert (Wiener, 28) demonstrated that Rh-negative blood
contains a special agglutinogen, designated Hr by them because of its appar-
ently reciprocal relation to Rh. Race and Taylor (Wiener, 28) independently
discovered an agglutinogen which they called St, and showed that St was re-
lated to rh» as M is related to N. Wiener has proved that Hr and St are
identical, so that the designation St has been abandoned. Since the Hr
kantigen first found is reciprocally related to rh 1 , Wiener suggested that it
be designated as hr'»
Sensitization to the Hr factors can cause clinical complications similar
to -those produced by Rh sensitization, namely, intragroup hemolytic trans-
fusion reactions and eiythroblastosis fetalis. Hotrcver, the Hr factors are
far less antigenic than the Rh factors, so that such cases are quite rare.
Yet Hr antisera arc necessary to resolve clinical problems caused by sensi-
tization to factors other than Rh, and for the selection of Hr-negative
donors to be used for transfusing patients sensitized to one of the Hr
factors. Another important application of the Hr antisera is for a presump-
tive test for heterozygosity or homozygosity of Rh-positive husbands of Rh-
negative prospective mothers whc are known to be sensitized to the Rh factor.
Still another application is in disputed paternity cases, since the Rh-IIr
test considerably increase the chances of excluding a falsely accused m*n.
Thus at present, three Rh positive factors (agglutinogens) ore recognized,
namely, Rho, rh 1 and rh",
Wiener's designation Fisher's designation
rh» C
Rho D
rh" E
Likewise, there are three Rh negative factors: hr», Hro, and hr".
Wiener's designation Fisher's designation
hr' c
Hro d
hr" e
It is perhaps unfortunate that two systems of designating the Rh factors
are presently in use but it is not impossible to learn both classifications.
Workers will find it helpful to use the British or Fisher type of nomencla-
ture when talking about the possibilities of immunization to the Rh factors
and in talking about which genec an individual may have inherited from his
parents.
The Rh factors as well as the A and B factors are inherited character-
istics of an individual just as the color of one's eyes or the shape of one's
face, etc. An individual gets a pair of allelic genes—one gene from each
parent each carrying one Rh and Ilr blood factors; these groupings remain
with him unchanged during his lifetime. If the individual has children, his
children receive one of his two genos to go along with one of the mother's
genes and thus characteristics are passed from one generation to another.
It is a biological law that an individual who possesses a blood factor
lacks tho capacity to produce antibodies for that particular blood factor.
On the other hand, an individual tiho does not have a particular blood factor
may oroduce antibodies for that factor.
How are antibodies produced in individuals? It is a well known fact
that typhoid vaccine is given to individuals to stimulate antibodies which
will act upon typhoid bacilli if the individual is later exposed to them.
The antibodies are produced in an individual's system so that they will pro-
tect that individual when the foreign bacteria attempt to get a foothold in
the individual's body. This is what is meant by immunization. This is why
vaccines are given. Mow with blood, the same thing happens. For some
reason, presently unknown, tho (D) factor in blood i;3 a uore potent producer
of antibodies in an individual than the (C), (E), (c), (d), or (e). This is
why it is so connon to find persons immunized to the (D) factor. It is
probable that more than half of the individuals who lack the (D) factor will
produce anti-D antibody following the transftision of (D) cells into them.
Exactly why the other fifty percent do net become immunized is not known.
The rh' (C), and the rh" (E) factors potentially can and occasionally
6do produce antibodies in individaals lacking them. As will be seen from the
chart below, the large majority of all persons who lack the (C), (D), and (E)
factors are true rh-negative (cde).
Table 1. Reactions with Rh anti-serum.
Rh blood
tea ^Anti-RhoCD) t Anti-rh'(C) t Anti-rh"(E) t
Distribution
in white
pop, in U.S.
Rho
Rho»
Rho"
Rho'Rho"
rh«
rh»«
rh»rh»»
rh-negative
or Hr »Hr "
cDe
CDe
cDE
CDS
Cde
cdE
2.0
53.0
15.0
15.0
US
0.5
CdE negligible
cde
85.0 69.5 30.5
13.0
100.0$
In Asiatics, American Indians, and peoples in the Pacific, the CDe and cDE
types predominate. Among Negroes, cDe is the most common. CDe and cDE are
the predominating types found in the peoples of Europe.
Essential difference between agglutination and conglutination is as
follows:
Rh positive Anti-Rh agglutinins Agglutination
red cells (bivalent antibodies)
Rh positive Anti-Rh blockers Conglutinin Conglutination
red cells (univalent antibodies) (I Protein)
Agglutination proceeds in a single step. Each molecule of agglutinin
being bivalent (in the chemical sense) links two red cells together, and in
this way clumping of cells occurs in any isotonic medium. For the agglutin-
ation test, the most satisfactory medium is saline solution.
7In conglutination sera, the antibody combines with the red cells but
without clumping them. In the presence of whole plasma or serum, however,
clumping will occur because plasma and serum contain the so-called protein
or conglutinin which is absorbed onto the sensitized cells, thus bringing
about clumping, Conglutinin is relatively thermostable but sensitive to
even slight dilution by aqueous solutions. Conglutinin or X protein seems
to be a colloidal complex of albumin, globulin, and phospholipid into which
it readily dissociates upon dilution*
"A" substance is commercially isolated as precipitate from a tryptic
digest of hog gastric mucin. "B" substance from the digest of the glandular
portion of horse gastric mucosa. Tn 10 ml. of a mixture of both substances,
th*»re are 7 "gnu of "A" and 5 mgm. of "B" substance. This product is used
for the following processes:
1-neutralization of anti-A and anti-B agglutinins in universal donor
blood.
2-neutralization of group specific antibodies in the method of antibody
determination and titration.
3-neutralization of anti-Rh typing serums in the manufacturing process.
U-injection to stimulate the production of anti-A and anti-B agglu-
tinins.
In the field of immunology there were few laboratory procedures which
were capable of yielding information of such clinical accuracy as did the Rh
antibody titrations (1, 2, 3). For example, the presence of low-titer
agglutinins for pathogenic organisms such as typhoid, brucella or tularemia,
often may be demonstrated in the serums of individuals suffering with a
disease, and yet no other confirmatory evidence of the disease can be obtain-
ed.
On the other hand, individuals whose serums contain Rh antibodies almost
invariably give a history of events, as transfusions or pregnancies, which
account for the presence of the antibody. The opportunity to furnish such
3valuable laboratory information to oDetetricians ?.nd j>ediatricians raake it
imperative to use accurate laboratory procedures in Eh antibody titrations,
LABORATORY PROCEDURES
In testing serums for Rh antibodies, the following procedures are used:
Serum
Specimens of blood ( ? cc or more) to be tested are collected in clean,
dry 1'asserman tubes,
(1) Centrifuge and separate serum from clot.
(2) Make a 1-3 dilution of the serum using one part serum and
two parts 30 percent bovine albumin (Armour),
Red Cells
Various cells should be tested with serums of known specificity in order
to select the desired Rh types. It is important to select Group individ-
uals who may be always readily available. Rho'Rho'* (CDE) or Rho* (CDe) and
RhoM (cDE) cells may be u3ed, but if antibody is found to be present, pure
Rho (cDe), rh* (Cde), and rh" (cdE) cells must be used to determine the
specificity cf the serum antibody.
(1) Cells for antibody testing are collected in potassium ammonium
oxalate, using one drop of oxalate, (2 mg.) per 1 cc of blood.
(2) Wash 1 cc freshly drawn oxalated blood with sterile 0.8£ per-
cent saline in centrifuge tube. Aspirate supernatant and add 0.2 cc of
9packed washed cells to 10 cc of saline for agglutinating titrations and 0.2 cc
of washed cells to 10 cc of 20 percent bovine albumin for "blocking" antibody
titrations.
Slide Titration Method
(1) Prepare a serum dilution using one part of serum and two parts
of 30 percent bovine albumin.
(2) Place one drop of the 1:3 dilution of serum in center of glass
slide.
(3) On the same slide place two drops of Rh specific cells.
(U) With a wooden applicator mix thoroughly in circular motion in
both directions. Cover most of the slide with the mixture.
(5) After the serum and cells are thoroughly mixed put slide on the
plate of a warm (U5-.S0 ) viewing box and start a stop watch.
(6) Rock the viewing box and observe slide for two minutes or until
complete reaction (agglutination) takes place if less than two minutes. Ob-
serve for two minutes as after that time drying takes place.
(7) The cells in the mixture will remain dispersed if no antibody
is present. If antibody is present, agglutination will appear in less than
two minutes and usually before one minute.
(8) Note and record appearance tir;e of agglutination and completion
time. If not complete (It) in two minutes note degree of completeness express-
ed as 1, 2, or 3.
(9) If 1:3 dilution gives an avid reaction and completes in two
minutes or less, then make a 1:10 dilution using one part serum and nine
parts of 30 percent bovine albumin. Mix thoroughly and test in same manner
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as the It 3 dilution. If It 10 dilution gives a strong reaction, make a It 100
dilution of the serum using one part of the It 10 dilution and nine parts of
albumin and test on slide with same cells. If a 3 or h reaction is still
obtained then make up a It 1000 dilution using one part of It 100 dilution and
nine parts of albumin, and test.
(10) These preliminary tests on the slide determine how far to carry
the test tube titration.
Tube Titration Method
The approximate amount of antibody having been determined by slide
tests, a rack of tubes are sot up and numbered according to the dilution of
serum in the tubes as 1, 2, U, 8, 16, etc.
Saline and albumi n titration series are made. Saline antibody will
react in both saline and albumin. "Blocking" antibody will cause clumping
in albumin, serum, or plasma, but not, in saline.
(Exaraplet Serum tested gives an appearance time of approximately 30
seconds with a 2 reaction on slide with 1:100 dilution, the titer should be
around 2-k x 100, or 200-U00. Tubes are set up from the undilute serum to
a dilution 1:512 or 10 tubes.
ltlO dilution of serum set up to lt61i
ltlOO dilution cf serum set up to 1:8
(1) Using a 1 cc pipette deliver to bottom of all tubes but the
first 0.1 cc of 20 percent albumin for blocking titration or 0.1 cc saline
for "agglutination" titrations.
(2) With 0.2 cc pipette deliver 0.1 cc of serum or serum dilution
to the first tube and 0.1 cc of serum or serum dilution to the second tube.
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Mix the content of the second tube three tir.»s and discard pipette. With a
clean pipette transfer 0.1 cc from second tube to third tube and mix, etc.
When last tube has been mixed, draw up 0.1 M and discard,
(3) With 1 cc pipette add 0.1 cc of 20 percent cell suspension to
each of the tubes. (For agglutinating titrations, use saline suspended cells.
For conglutinating titrations, use albumin suspended cells.)
(U) Shako tubes well and place in 37° water bath for 30 minutes—
if albumin suspended cells ware used. Leave at room temperature if saline
suspended cells were used.
(5) After incubation, shake tubes vigorously for one minute and
spin at 2000 rpm for one minute.
(6) Shake tubes just enovtgh to dislodge button from bottom of tube.
(7) Observe for agglutination .microscopically. Record as end point
the tube containing the greatest dilution of serun which causes definite macro-
scopic agglutination.
-
RAPID ESTIMATION OF ANTIBODY BY SLUE TEST
While much has been written concerning tube titration procedures, the
value of slide titrations was less -sell known. The slide test was found to
be rapid and reasonably accurate in the estimation of antibody titer. It
had one distinct advantage over the tab'? test in that aone phenomena which
were commonly associated with high-titerod serums were not noted when whole
blood was used with blocking antibody on the slide. Using the slide test for
the preliminary estimation of antibody content, the limit of serial dilutions
necessary to prove the titer in the tube can be estimated.
The slide method of estimating antibody titer has certain limitations.
(1) The relation cf antibody titer and appearance time of agglutination nust
be established for a given teat cell. Cells from various individuals react
diffei'ently with regard to the appearance time of agglutination and complete-
ness of reaction. (2) The technique and time involved in nixing the serum
dilutions and whole blood must be relatively standard. The time lapse between
mixing and the appearance of agglutination must be carefully recorded, pre-
ferably with a stop watch. (3) The serum should be titered by the tube
method for confirmation.
A 30 percent solution of bovine albumin has been found to be most useful
as a diluent for the serum to be tested. It is important that rt-d blood cells
from blood having a hematocrit within normal range (hO-hB%) be used.
Five cc. specimens of blood were secured from the Topeka Blood Bank.
Each specimen was typed as to the A-B-0 groupings and with anti-Rho sera.
When a specimen failed to agglutinate, it was then tested with anti-rh* sera
and anti-rh' « sera. Approximately fifty bloods were tested. A suitable rh»,
group donor was found and upon his consent, specimens were drawn when
necessary to insure fresh cells. The cells were collected into sterile
flasks containing ACD Solution.
ACD Solution (Baxter-AlsRver) t
Sodium citrate, trisodiura dihydric 2.1 gm 1.6 gnu
METTODS OF EXAMINATION
Citric acid, monohydric
Dextrose, anhydrous
Distilled water, up to
0.66 gm 0.5 gm.
2.0 gm 1.5 gm.
100.0 ml 75.0 ml.
Storage temperature 5-10° centigrade.
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Blood Group Specific Substances A and B Solution (Sharp and Dohme, Inc.)
were added at the rate of 10 cc. per 5>00 cc. of Group blood before injection
into the rabbits.
Three rabbits were injected with identical amounts and at the same inter-
vals.
Injection ifo.l: 2.0 ml. of 10$ cell suspension.
Injection iio.2: lwO ml. of 10$ cell suspension.
Injection No. 3* 5.0 ml. of 10$ cell suspension.
Injection No.lt: 5*0 ml. of 10$ cell suspension.
Injection No.5: 5.0 ml. of 20$ cell suspension.
Injection No .6: 5.0 ml. of 20$ cell suspension.
The rabbits were injected at intervals of three to four days. (Monday and
Friday). At the end of the injection period, a week was allowed to pass
before approximately forty cc. of blood was removed from each rabbit (asepti-
cally from the heart). The blood was allowed to clotj then centrifuged and
the serum removed. The serum was measured into five cc. portions, placed in
sterile test tubes (with screw caps), and placed in the deep freeze until
time for titration determinations to be made.
Slide avidities were run on each serum using Rho 1 cells, rh* cells, and
rh negative cells, by the following procedure:
A serum dilution of 1 part serum to 2 parts of 30 percent bovine
albumin was prepared. One drop of the dilution was placed on a
clean glass slide to which was added two drops of the known Rh
specific cells. After thoroughly mixing, the cells were observed
for two minutes—noting the appearance and the completion time.
The titrations were run in duplicate using saline and albumin dilutions
with known Rho» M positive, N negative cells, rh' cells, and rh negative M
positive, N negative cells. Each titration series was carried to the 1:256
dilution.
Tube 123US6 7 8 9
Dilution 1:1 1:2 Uk 1:8 1:16 lt32 1:6k 1:128 1:2^6
Saline or
Albumin 0,1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Serum 0.1 0.1 Mix and carry over 0.1 to next tube; repeat.
2% cell
Suspension 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0#1
Shake tubes 10 seconds and place in a 37 degree water bath for 30
minutes if albumin was used. Leave at room temperature if saline
was used. After incubation, shake 1 minute and centrifuge tubes
at 2000 rpra for 1 minute. Dislodge button from bottom of tubes
and read macroscopically.
RESULTS
Serum NO. 1
Slide avidity:
Rho' 2 plus @ 2 minutes.
rh» Appearance tiaa ® 20 seconds; complete @ 2 minutes.
rh negative.... Negative ~> 2 minutes.
Titration:
Saline:
Rho» (1) 2 2 1
(2) 3 2
rh« (1) h k h 3 2
(2) k 3 k h 3 1
rh-
Albumin:
Rho» (1) 1
(2) 2 1
rht (1) h h 3 1
(2) 3 h 2
rh-
15
Serum No. 2
Slide avidity:
Rho* Appearance time • 35 seconds; 2 plus 1 2 minutes.
rh*. Appearance time @ 15 seconds? complete @ 2 minutes.
rh negative.... Negative I 2 minutes.
Titration:
Saline:
Rho* (1) k 3 2
(2) 1 K 2
rh« (1) U h h h 3 1
(2) h k 3 3 2
rh- a
Albumin:
Rho» (1) 3 1
(2) 3 2
rh« (1) h h U 3
(2) h 3 U 3 2
rh-
Serum No. 3
Slide avidity:
Rho 1 Appearance I 30 seconds; 2 plus ft 2 minutes.
rh 1 Appearance % 20 seconds; complete ® 2 minutes.
rh negative.... Negative <? 2 minutes.
Titration:
Saline:
Rho« (1) 2 i
(2) 3 i 2 1
rh« (1) U 3 1* h 2
(2) U k 3 h 1 1 1
rh-
Alburain:
Rho« (1) 3 1
(2) U 2
rh» (1) h u 3 3 1
(2) i 3 U 2 1 1
000000000
16
SUMART
'Hie results 6eciaQd to indicate that a suitable titer can be achieved.
Agglutination occurred in dilutions up to 1:16 and It 32 after six injections.
In present day procedures of producing rh' serun from human sources, some-
times months to years are required to secure a titer sufficiently high for
commercial preparations.
Many duplications should be run before a suitable procedure could be
established. There is doubt as to whether this agglutination of the cells
is due entirely to the antigens present on the known cells an?, the antibody
produced in the sera or whether it is due to the human-raboit element.
Agglutination due to the A, B, and group, to the Rh factor, and to
the M, N, and MN factor has been established. Since the Rho« I positive,
N negative cells were agglutinated, the serum could not have contained anti-
bodies against the N factor. Since the rh, K cells were not agglutinated,
the serum could not have contained antibodies against the I factor. The P
factor is not commonly found in rabbit sera. The more recently found factors
were not considered.
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The Rh or rhesus blood factor has supplied the key to two medical
mysteries, namely, the cause of hemolytic transfusion reactions in patients
receiving blood of their own A-B-0 group, and the cause of an obscure blood
disease of newborn infants known as erythroblastosis fetalis.
Since the seventeenth century, difficulty has arisen from blood trans-
fusions, due to some unknown factors. In 1900, searching for individual
differences in human blood, Landsteiner selected the simplest technique
possible, namely to mix the serum of one individual with the red cells of
others. By this method, he found that the blood fell into three blood
groups. The fourth and rarest group, AB, was not discovered until the
following year by DeCastello and Sturli.
Discovery of the agglutinogens H, N, and P came next but have proved
of little importance for the selection of donors for blood transfusions,
because isoantibodies for M, N, and P occur only rarely in human seta*
Intragroup reactione seamed to indicate that there were more factors
involved. Not until after 1?37» l-andsteiner, Viener, and others explained
that these reactions might be due to the Rh factors. After much work, very
potent sera of human origin have been produced and made available to the
public.
After observing the lengthy process of producing the anti-rh« sera of
human origin (sometimes require injections over a period of a year or more
to secure a titer sufficient for testing) and reading many articles and
reviews of previous work, I wondered if—by injecting the New Zealand white
rabbit with the cells of an individual whose type was that of rh 1—a suit-
able anti-sera might be produced in a shorter time.
METHODS OF EXAMINATION
Five cc. specimens of blood were secured from the Topeka Blood Bank,
Each specimen was typed as to the A-B-0 groupings and with anti-Rho serum.
i-Jhen a specimen failed to agglutinate, it was then tested with anti-rh»
serum arxi anti-rhn serum. Approximately fifty bloods were tested. A suit-
able rh», group donor was found and upon his consent, specimens were drawn
when necessary to insure fresh cells. The cells were collected into sterile
flasks containing ACD Solution. Blood Group Specific Substances A and B
Solution was added at the rate of 10 cc. per £00 cc. of Group blood before
injection into the rabbits.
Three rabbits were injected with identic al amounts and at the same
intervals.
Injection No.l: 2.0 ml. of 10% cell suspension.
Injection No. 2: U.O ml. of 10$ cell suspension.
Injection No. 3? 5.0 ml. of U|l cell suspension.
Injection No.l*: 5.0 ml. of 10% ceil suspension.
Injection No.5: !?«0 ral. of 20$ cell suspension.
Injection No. 6: 5.0 ral. of 20$ cell suspension.
The rabbits were injected at intervals of three to four days. At the
end of the injection period, a week was allowed to pass before approximately
forty cc. of blood was removed from each rabbit (aseptically from the heart).
The blood was allowed to clot; then centrifuged and the serum removed. The
serum was measured into five cc. portions, placed in sterile test tubes
(with screw caps), and placed in the deep freeze until time for titration
determinations to be made.
Slide avidities were run on each serum using Rho' cells, rh» cells, and
rh negative cells, ay the following procedure:
A serum dilution of 1 part serum to 2 parts of 30 percent bovine
3albumin was prepared. One drop of the dilution was placed on a
clean glass slide to which was added two drops of the known Rh
specific cells. After thorough mixing, the cells were observed
for two minutes—noting the appearance and the completion time.
The titrations were run in duplicate using saline and albumin dilutions
with known Rho* cells, rh 1 cells, and rh negative cells. Each titration
series was carried to a dilution of 1:2£6.
Tube No. 123US6 7 3 9
Dilution 1:1 1j2 1th 1:8 lOl 1:32 It 6k 1:128 Ut$fl
Saline or
Albumin 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Serum 0.1 0.1 Mix and carry over 0.1 to next tubej repeat.
2% cell
fuspension 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Shake tubes 10 seconds and place in a 37 degree water bath for
30 minutes if albumin was us«d. Leave at room temperature if
saline was used. After incubation, shake 1 minute and centrifuge
tubes at 2000 rpm for 1 minute. Dislodge button from bottom of
tubes and read macroscopically.
RESULTS
Serum No. 1
Saline: Rho' 1th Albumin: Rho 1 1:2
rh* 1:32 rh» 1:8
rh- rh-
Serum No. 2
Saline: Rho* 1th Albumin: Rho* ltU
rh» 1:16 rh» 1:16
rh- rh-
Serum ?fo. 3
Saline: Rho' lik abitndn: r?ho« 1:2
rh« 1:16 rh« 1:16
rh- rh-
The results seemed to indicate that a suitable titer can be achieved.
Many duplications should be run before a citable procedure could be estab-
lished.
